Table 2.

Geometric mean ratios of rifabutin and 25-O-desacetylrifabutin parameters with and without antiretroviral therapy

	GMR (90% CI)
	RBT 150 mg tiw with RBT 300 mg daily	RBT 150 mg tiw with RBT 150 mg daily	RBT 150 mg daily with RBT 300 mg daily
AUC0–24	0.8 (0.7 – 0.9)	0.4 (0.5 – 0.5)	1.6 (1.4 – 1.9)
AUC0–48*	0.6 (0.5 – 0.7)	0.4 (0.4 – 0.4)	n/a
Cmax(ng/mL)	0.5 (0.4 – 0.6)	0.5 (0.5 – 0.6)	1.0 (0.9 – 1.0)
C0(ng/mL)	0.7 (0.5 – 0.9)	0.2 (0.1 – 0.3)	3.4 (3.7 – 3.1)
Cmin24h(ng/mL)	1.2 (1.0 – 1.4)	0.5 (0.4 – 0.5)	2.7 (2.2 – 3.2)

*calculated by 2 times the AUC_0–24 for the RBT 300 mg daily and RBT 150 mg daily arms.

n/a – Not applicable.

GMR – Geometric mean ratio.

90% Cl – 90% confidence interval.

RBT 150 mg tiw – rifabutin dose of 150 mg three times per week (tiw) in combination with lopinavir/ritonavir based ART and isoniazid.

RBT 150 mg daily – rifabutin dose of 150 mg daily in combination with lopinavir/ritonavir based ART and isoniazid.

RBT 300 mg daily – rifabutin dose of 300 mg daily in combination with isoniazid.